Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|August 13, 2010
Nexera — the cleanest and fastest UHPLC ever to date
Shimadzu's new LC-30A Nexera is unsurpassed in high-speed and high-resolution analysis and productivity. It meets the needs of the most demanding markets such as pharmaceutical and the food industry.
Advertisement
UHPLC systems represent the latest development in liquid chromatography instrumentation. Beside enhancements necessary to operate with sub 2 µm particle columns, they differ from each other through their versatility in handling various applications on the same instrument without any changes.
Shimadzu’s new LC-30A Nexera is unsurpassed in high-speed and high-resolution analysis and productivity. It meets the needs of the most demanding markets such as pharmaceutical and the food industry.
Nexera pumps offer a flow range from 0.0001 ml/min up to 3ml/min with 130 MPa pressure and from 3.0001 up to 5 ml/min with 80 MPa pressure. This allows the use of longer columns for covering fast LC with high flow rates and short columns as well as highest resolution using long columns.
The new developed micro-reactor based mixer supports a small system volume and very short gradient delays. The Nexera autosampler provides reduced carryover compared to the previous instruments by keeping the direct injection with isolated metering system principle using 3 rinse solvents, various rinsing modes and design changes at needle and needle seal. To increase the throughput overlapping pre-treatment can be used. The pre-treatment capabilities expand the application range of this instrument.
The control unit contains a modified software in order to control the new modules and functionalities, e.g. the autosampler.
In addition to UV and PDA detectors, the brand-new and worldwide most sensitive and fastest RF-20A/20AXS fluorescence detectors can be applied with Nexera.
LC-30A Nexera can be used for semi-micro, conventional and UHPLC methods without changes on the flowline. It fulfils the demands of an all-round LC system with high reliability and robustness.
For further details please visit
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement